Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01760915 · ClinicalTrials.gov registry record
University of Wisconsin Severe Asthma Research Program III
A clinical trial, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- 107
- Enrollment target
NCT01760915: Completed study, sponsored by University of Wisconsin, Madison.
NCT01760915 is a clinical trial that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 107 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01760915 has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- 107 participants
- Enrollment target
Study Summary
The overall goal of this proposal is to better understand the basis of structural airway changes in severe asthma and how asthma exacerbations may contribute to their progression over time. The investigators propose to study a well-characterized cohort of adult and pediatric subjects with asthma using a multidisciplinary state-of-the-art approach. We hypothesize that severe asthma exacerbations, in some patients, are associated with incomplete recovery and activation of airway inflammatory cells in a regional distribution. The end result is a more permanent and less reversible airway obstruction that is a prominent feature of severe asthma.
Primary Outcome
Changes in airway function after a severe exacerbation, and longitudinally over 3 years, as measured by lung function.
Interventions
- OTHER NC100182 Hyperpolarized 3He
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 107 participants |
| Start Date | 2012-11-28 |
| Est. Completion | 2021-12-17 |
What the finished NCT01760915 record still lists
NCT01760915 is an observational study that tracks outcomes without assigning an intervention. The registered 107 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which NC100182 Hyperpolarized 3He is the first listed.
NCT01760915 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01760915 about?
NCT01760915 is a clinical study titled "University of Wisconsin Severe Asthma Research Program III". The overall goal of this proposal is to better understand the basis of structural airway changes in severe asthma and how asthma exacerbations may contribute to their progression over time. The investigators propose to study a well-characterized cohort of adult and pediatric subjects with asthma usi...
What is the current status of trial NCT01760915?
This trial is currently completed. The enrollment target is 107 participants. The study started on 2012-11-28. Estimated completion is 2021-12-17.
What interventions are being tested in trial NCT01760915?
The interventions under investigation include: NC100182 Hyperpolarized 3He (OTHER).
Who is sponsoring clinical trial NCT01760915?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05491668 · 107 participants
Physiological Assessment of Severe Coronary Stenosis for Informing Planned PCI
- NCT06041594 · 107 participants · NA
Treating Pulmonary Embolism With Laguna Thrombectomy System (TRUST)
- NCT06081426 · 107 participants · NA
Examining Neurobiological Mechanisms Underlying the Therapeutic Effect of the Ketogenic Diet in Bipolar Disorder (BD)
- NCT06527599 · 107 participants · NA
Screening in Trauma for Opioid Misuse Prevention - an Adaptive Intervention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI